ReviewClinical, cosmetic and investigational dermatology2026
The Multiorgan Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review.
Review in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are acute, life-threatening mucocutaneous reactions causing necrosis of external and internal body surfaces, thereby predisposing patients to multiorgan complications. Numerous internal organ systems are impacted by SJS-TEN, encompassing the skin, ocular, ear, nose, and throat (ENT), pulmonary, gastrointestinal (GIT), and genitourinary systems. The acute and long-term organ complications associated with SJS-TEN have not been comprehensively documented. The objective of this review is to systematically delineate multiorgan complications in cases of SJS-TEN. A comprehensive search of the available literature was conducted on electronic databases (PubMed and Scopus) published between 2019 and 2024, reporting SJS-TEN patients with multiorgan complications using predefined search terms and inclusion/exclusion criteria. The terms "Stevens-Johnson syndrome", "toxic epidermal necrolysis", "organ complication", "multiorgan involvement", and "sequelae" were used as keywords. We included 38 articles reporting SJS-TEN patients with multiorgan complications, comprising 15 reviews, 11 original studies, 9 case reports, and 3 case series; data were synthesized descriptively, and no quantitative meta-analysis was performed. Reported percentages therefore reflect the proportion of included studies reporting a given complication, not patient-level prevalence. Among studies providing extractable patient-level data, the mean age of the subject population was 36.72 ± 26.58 years, with female predominance (88.2%). Ocular involvement was the complication most frequently reported across the included studies (65.8% of studies), followed by pulmonary and genitourinary involvement (26.32% of studies each) and skin complications (21.05% of studies). The most frequently reported ocular complications were trichiasis, distichiasis, and symblepharon, each noted in 60% of studies reporting ocular involvement. SJS-TEN represents a severe delayed-type hypersensitivity reaction with a high risk of long-term mucocutaneous disabling effects. Given the heterogeneity of the included study designs, these findings should be interpreted as an indication of how frequently each complication has been reported in the literature rather than as an estimate of true patient-level risk. This systematic review emphasizes the importance of clinician awareness to ensure early detection of multiorgan complications associated with SJS-TEN, thereby ensuring optimal, multidisciplinary patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.